As cancer rates increase in China and more people use western medicines, Swiss pharmaceutical Roche Holding AG expects sales to double by 2010, the Wall Street Journal reported. The company has a single joint venture in China, Shanghai Roche Pharmaceutical, a 70-30 deal with Shanghai Sanve Pharmaceutical. It expects to see annual revenue increases of up to 16% until 2010, doubling the US$191.2 million sales recorded in 2005. In recent years, some 1.6 million people have been diagnosed with cancer every year.
You must log in to post a comment.